Does a GLP-1 improve cholesterol in women with PCOS?
# Does a GLP-1 improve cholesterol in women with PCOS?
If you have PCOS, a cholesterol result that came back "off" can feel like one more thing your body is doing without your permission. It is a fair worry, and it is not in your head. The lipid problems that travel with PCOS are real, and they are closely tied to the insulin resistance underneath the whole condition. So the honest question is not whether these medicines melt fat. It is whether they do anything measurable for the cholesterol numbers your clinician actually watches. Here is what the research shows, hedges and all.
Key takeaways
Dr. Linda's take
I want to be straight with you, because cholesterol is one of those numbers that gets used to scare people. The research here is genuinely encouraging in places and genuinely thin in others, and you deserve both halves of that sentence. What I see across the studies is a pattern that makes sense: as weight and insulin sensitivity improve, the lipid numbers often soften too. That is believable and it is worth something. It is also not a guarantee, and the studies are small enough that I would not promise you a specific result.
These medicines are approved for type 2 diabetes and for long-term weight management, and using them specifically for PCOS lipids sits outside those approvals, so it is a decision a clinician makes with you one person at a time. If you want a low-pressure way to see whether this even fits your body and your labs, our two-minute quiz is a gentle first step.
Why is cholesterol a problem in PCOS?
Cholesterol trouble is not a coincidence in PCOS, and it is not a moral failing about diet. Women with polycystic ovary syndrome frequently have lipid abnormalities, and up to 70% of patients have dyslipidemia. That is a striking number, and it reframes the issue as part of the condition rather than something separate you happened to develop.
The reason sits upstream, in the same place most of PCOS starts. In polycystic ovary syndrome, insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone binding globulin production. High circulating insulin does not only nudge androgens upward; it also shifts how your body handles fats, which is a big part of why the cholesterol and the hormones so often go wrong together. If you want the fuller version of that story, our explainer on insulin resistance in PCOS walks through it slowly.
Does a GLP-1 improve cholesterol in women with PCOS?
This is the question that actually matters, so let me give you the direct evidence first. In a 2025 meta-analysis of eight randomized trials in 526 women with polycystic ovary syndrome, semaglutide significantly improved body mass index and lipid profiles, with greater effects at higher doses and in women with obesity. That is a real signal in the direction most people would want, and it lines up with what these medicines do elsewhere.
The picture holds up when you look at another medicine in the class. In a 2025 meta-analysis of nineteen randomized trials in 1657 women, liraglutide combined with metformin reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol compared with metformin alone. So across two of the most studied options, the lipid numbers moved in a favorable direction, which is a reasonable basis for cautious optimism rather than hype.
How strong is the evidence, really?
Here is where honesty has to lead, because the encouraging headlines sit on a thin foundation. In the 2025 semaglutide meta-analysis, the overall evidence quality was moderate to low based on a GRADE assessment. In the liraglutide and metformin meta-analysis, the overall certainty of evidence was low due to risk of bias and heterogeneity. Low to moderate certainty does not mean the findings are wrong; it means the studies are small and varied enough that the size of the effect could shift as better trials arrive.
The mixed results across studies make that caution concrete. In a 2025 meta-analysis of randomized trials of GLP-1 receptor agonists in women with polycystic ovary syndrome, lipid profiles including total cholesterol, HDL, LDL and triglycerides were measured as secondary outcomes. In that analysis, GLP-1 receptor agonists were associated with a reduction in HDL, while total cholesterol, LDL and triglycerides were unchanged. That is a noticeably less rosy result than the semaglutide-specific numbers, and it is exactly why single studies should not be read as the last word.
The population you study also changes the answer. In a 2024 meta-analysis of four randomized trials in women with polycystic ovary syndrome and obesity, there was no significant difference in total cholesterol between GLP-1 receptor agonists and placebo. In that analysis, GLP-1 receptor agonists were associated with a significant reduction in serum triglycerides compared with placebo. So one lipid marker moved and another did not, in the same study, which is a good reminder that "cholesterol" is really several different numbers that do not always respond together.
How would a GLP-1 change lipids in PCOS at all?
The mechanism is not a mystery, and understanding it helps set expectations. In the 2025 meta-analysis, GLP-1 receptor agonists effectively reduced body weight, BMI and insulin resistance in women with polycystic ovary syndrome. Those are the same levers that tend to pull lipids in a better direction, which is why most researchers read the cholesterol changes as a downstream effect of losing weight and improving insulin sensitivity rather than a direct action on your cholesterol.
That framing matters for what you should expect. If the lipid benefit rides on the metabolic benefit, then the people who see the most weight and insulin change are often the ones who see the most lipid change, and the effect is not automatic. It is also worth knowing these medicines are not the only tool that touches PCOS lipids. In a 2026 network meta-analysis of twenty-nine randomized trials, SGLT-2 inhibitors ranked first for lowering triglycerides and total cholesterol in polycystic ovary syndrome, ahead of GLP-1 receptor agonists. The researchers are also the first to say the work is not done. The authors of that meta-analysis concluded that further studies are needed to explore the long-term effects of GLP-1 receptor agonists on lipid profiles in polycystic ovary syndrome. If you are weighing your options, our guide on metformin or a newer medicine for PCOS lays out the tradeoffs in plainer detail.
Frequently asked questions
Will a GLP-1 fix my cholesterol if I have PCOS?
Not on its own, and it helps to be honest about that. The evidence points to modest, favorable shifts in some cholesterol markers for many women, but the studies are small and the certainty is rated low to moderate. Because the lipid benefit seems to ride on weight and insulin changes, the size of any improvement depends on your starting point and how your body responds, which is a conversation for you and a prescriber, not a promise from an article.
Does the benefit come from the medicine or from losing weight?
The most likely answer is both, tangled together. The cholesterol changes in these studies tend to move alongside weight loss and improvements in insulin resistance, so the medicine appears to help lipids mainly by improving the metabolic picture rather than acting on cholesterol directly. That is not a knock on the effect; it is just the honest mechanism.
Are there other PCOS symptoms these medicines affect?
Yes, and cholesterol is only one thread. The same insulin-lowering effect connects to hormones and cycles, which is why some women ask about testosterone in women with PCOS or about menstrual regularity in women with PCOS. None of those effects are guaranteed, and each is its own case-by-case clinical question.
Is a GLP-1 approved to treat cholesterol in PCOS?
No. These medicines are approved for type 2 diabetes and for long-term weight management, not for PCOS or for treating cholesterol in PCOS, so any such use is a case-by-case decision made with your own prescriber. That is the kind of question a licensed clinician should answer for your situation, not an article.
References
1. Medicina (Kaunas) (2024). The Current and Emerging Role of Statins in the Treatment of PCOS: The Evidence to Date. PubMed PMID 38399531. https://pubmed.ncbi.nlm.nih.gov/38399531/ (Accessed 2026-07-26).
2. Nature reviews. Endocrinology (2011). Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. PubMed PMID 21263450. https://pubmed.ncbi.nlm.nih.gov/21263450/ (Accessed 2026-07-26).
3. Gynecological endocrinology (2025). Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients. PubMed PMID 40960939. https://pubmed.ncbi.nlm.nih.gov/40960939/ (Accessed 2026-07-26).
4. Diabetes, obesity and metabolism (2025). Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta-analysis. PubMed PMID 40855964. https://pubmed.ncbi.nlm.nih.gov/40855964/ (Accessed 2026-07-26).
5. Scientific reports (2025). Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. PubMed PMID 40360648. https://pubmed.ncbi.nlm.nih.gov/40360648/ (Accessed 2026-07-26).
6. Journal of diabetes and its complications (2024). The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. PubMed PMID 39178623. https://pubmed.ncbi.nlm.nih.gov/39178623/ (Accessed 2026-07-26).
7. Journal of ovarian research (2026). The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis. PubMed PMID 41862977. https://pubmed.ncbi.nlm.nih.gov/41862977/ (Accessed 2026-07-26).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-26.*
Keep reading
Does a GLP-1 lower blood sugar after menopause?
After menopause, insulin resistance tends to rise. Dr. Linda Moleon, MD explains how GLP-1 medicines lower blood sugar and what that means for postmenopausal women.
Are Black and Latina women more likely to stop a GLP-1 early?
Black and Latina women face real gaps in staying on GLP-1 care. Dr. Linda Moleon, MD on what the data show and the structural reasons behind early discontinuation.
Can a GLP-1 lower blood pressure during perimenopause?
Blood pressure often creeps up in perimenopause. Dr. Linda Moleon, MD explains what weight-loss trials show about GLP-1 medicines and blood pressure, and what they are not.
How do you start a GLP-1 in Jacksonville?
If you are starting a GLP-1 in Jacksonville, the hard part is usually the process, not the medicine. Dr. Linda Moleon, MD walks through eligibility and first steps on the First Coast.
Can a GLP-1 improve menstrual regularity in women with PCOS?
In PCOS, irregular periods are tied to insulin resistance and weight. Dr. Linda Moleon, MD reviews what the research shows about GLP-1 medicines and menstrual regularity.
Do GLP-1 medicines lower diabetes risk for Black and Latina women?
Black and Latina women carry more diabetes risk. Dr. Linda Moleon, MD reviews what the trials show about GLP-1 medicines and diabetes prevention, and whether the evidence applies.